Pre-clinical data shows potential for FASN inhibition as mechanism of action to treat acne Phase 3 clinical trial of denifanstat in moderate to ...

Please provide your email address to receive an email when new articles are posted on . The photopneumatic device improved acne in 66.7% of patients in this 7-week trial. Improvements were seen across ...

An acne management guideline was updated, which includes new considerations for isotretinoin, hormonal therapies, new topical ...

A look at the most common medications used in patients with acne. Casey Butrus, PharmD: Hilary, we have many different treatment options for acne, different mechanisms of action that have been around ...

The treatment of acne ( Table I) [1,2,3,4,5,6] is based upon its severity (mild, moderate, severe) and the type(s) of lesion(s) present (noninflammatory, inflammatory, mixed). In general, the ...

Secured equity financing with gross proceeds of $175M in April 2026Phase 3 clinical trial of denifanstat in moderate to severe acne patients for ...

Please provide your email address to receive an email when new articles are posted on . IDP-126 — a combination of clindamycin, adapalene and benzoyl peroxide — reduced acne severity in about half of ...

Denifanstat met all endpoints in a Phase 3 acne trial and showed favorable tolerability. Sagimet also launched a Phase 1 trial for TVB-3567. Sagimet Biosciences announced that its oral fatty acid ...

BRISBANE, Calif.--(BUSINESS WIRE)--Ninety percent of moderate to severe acne sufferers said having acne-free skin would dramatically change the way they live their life, according to a new survey ...

Among nearly 20 different agents and treatment combinations, topical triple-agent fixed-dose combination (FDC) gel emerged as the most efficacious for moderate-to-severe acne. Researchers who ...

It’s the bane of many people’s existences – acne. It can feel like the only thing you see when you look at a photo or when you’re putting on makeup. Acne can cause not only skin discomfort and ...